Pediatric Studies: FDA Pushes Earlier Dermatitis Trials; Will It Push Others Next?
Executive Summary
Advisory committee encourages studies with young children in the disease; emphasis on research as a safety tool could have broader policy implications.
You may also be interested in...
Pediatric Studies Of Systemic Atopic Dermatitis Drugs Should Start Earlier, US FDA Says
Sponsors generally should begin pediatric studies after obtaining initial evidence of efficacy and safety from early phase adult trials rather than waiting until initial approval in adults, agency says in a new draft guidance; move toward earlier timeline for pediatric research aligns with recommendations from a 2015 advisory committee, and patient and professional groups.
United Therapeutics Wins Unituxin Approval, Pediatric Priority Review Voucher – With NIH Support
The National Cancer Institute conducted the clinical trials of Unituxin for treatment of pediatric high-risk neuroblastoma and teamed with United for manufacturing and commercialization.
Adaptive Trials Guidance For Pediatric Drugs Will Draw On Device Advice
FDA’s centers may slingshot development work on how best to use control data.